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Objective: Individuals with pre-existing chronic illness have shown increased anxiety and 
depression due to COVID-19. Here, we examine the impact of the COVID-19 pandemic on 
emotional symptomatology and quality of life in individuals with Progressive Multiple Sclerosis 
(PMS).  
Methods: Data were obtained during a randomized clinical trial on rehabilitation taking place at 
11 centers in North America and Europe.  Participants included 131 individuals with PMS. Study 
procedures were interrupted in accordance with governmental restrictions as COVID-19 
spread.  During study closure, a COVID Impact Survey was administered via telephone or email 
to all participants, along with measures of depressive symptoms, anxiety symptoms, quality of 
life and MS symptomatology that were previously administered pre-pandemic.   
Results: 4% of respondents reported COVID-19 infection. No significant changes were noted in 
anxiety, quality of life, or the impact of MS symptomatology on daily life from baseline to 
lockdown. While total HADS depression scores increased significantly at follow up, this did not 
translate into more participants scoring above the HADS threshold for clinically significant 
depression. No significant relationships were noted between disease duration, processing speed 
ability or EDSS and changes in symptoms of depression or anxiety. 
Most participants reported impact of the virus on their psychological well-being, with 
little impact on financial well-being. Perceived impact of the pandemic on physical and 
psychological well-being was correlated with the impact of MS symptomatology on daily life, as 
well as changes in depression. 
Conclusions:  Overall, little change was noted in symptoms of depression or anxiety or overall 
quality of life.  
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The Emotional Impact of the COVID-19 Pandemic on Individuals with Progressive 
Multiple Sclerosis 
Coronavirus disease 2019 (COVID-19) was declared a pandemic on March 11, 2020 by 
the World Health Organization [1].  Neurological involvement is common in COVID-19, with 
greater symptoms in more severe cases [2]. Individuals with underlying neurological impairment 
are vulnerable to infection, and those infected have worse outcomes [3].   
Individuals with Multiple Sclerosis (MS) are typically on immunosuppressive/modulating 
medication placing them at-risk of infection from viruses [4] and are hypothetically at-risk for 
developing more severe forms of COVID-19 [5]. These individuals additionally have increased 
vulnerability to the neuropsychiatric concomitants of COVID-19, due to pre-existing 
neuropsychiatric symptomotology [6].  The COVID-19 pandemic has shown enormous 
psychological and social impact in the general population [7], not unlike other infectious diseases 
[8].  Mental health symptoms that can significantly impair functioning in otherwise healthy 
individuals [9], including stress, helplessness, and fear of becoming ill and dying have been 
observed [10,11]. The requirement to remain in quarantine has resulted in anger, confusion, 
anxiety and stress [12]. A recent systematic review and meta-analysis reported a 32% prevalence 
of anxiety and 34% prevalence of depression in the general population [13] with higher rates in 
females [14-18] and individuals reporting symptoms consistent with COVID-19 and poor 
perceived health [18].  
Pre-existing chronic illness is thus associated with increased psychiatric distress due to 
the spread of COVID-19 [18,19], specifically increased stress, anxiety and depression [7,18,20], 
placing individuals with MS in a uniquely vulnerable position to experience greater psychiatric 
symptomatology. We hypothesized that patients with Progressive Multiple Sclerosis (PMS) 
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(PMS) would demonstrate increased depression and anxiety and poorer QOL during the COVID-
19 pandemic, as compared with prior to the pandemic. 
Methods 
Data for the current study were obtained during the course of a multi-arm, randomized, 
blinded, sham-controlled trial that includes a follow up period. The parent study includes 4 arms 
with different combinations of Cognitive Rehabilitation (CR), Exercise (EX), Sham Cognitive 
Rehabilitation (CR-S) and sham exercise (EX-S). Participants are randomized to a study arm 
upon completion of baseline testing. Data are collected at 11 sites in 6 countries [Canada (1 site), 
US (2 sites), UK (2 sites), Denmark (1 site), Belgium (1 site) and Italy (4 sites)].  Outcome 
measures include neuropsychological assessment, Patient Reported Outcomes (PROs) and 
neuroimaging. See Feinstein et al [21] for full study protocol.  
Participants: Participants included 131 individuals with a clinically definite diagnosis of PMS 
(primary or secondary) of the 138 participants enrolled in the parent RCT. The mean age of the 
sample was 52 years (SD=6.9), with a mean disease duration of 14.4 years (SD=9.1). See Table 
1 for demographic data.  Given that these patients are generally the most impaired subtype of MS 
patients, they are thus the most likely to develop psychiatric symptomatology when facing a 
pandemic. 
Patients were recruited via specialized in and outpatient MS clinics, as well as via media 
advertising prior to the COVID-19 pandemic and were at various points in study participation 
when study procedures were stopped at all sites due to the pandemic. Prior to initial study 
enrollment, all potential subjects completed a 2-step screening procedure, including a pre-
screening examination in person or via telephone to collect basic information and a detailed face-
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to-face screening for neurological, psychiatric, cognitive, and medical variables. Inclusion and 
exclusion criteria are summarized in Table 2 by screening step.  
Procedure: The parent RCT received ethics approval at all institutions and a modification was 
approved at all institutions for additional PROs, including a COVID Impact Survey, to be 
administered during lockdown.  
Ongoing study procedures were interrupted at each individual data collection site in 
accordance with governmental restrictions as COVID-19 spread worldwide and all data 
collection sites were under lockdown orders.  During the study closure, all sites contacted 
participants by telephone on a weekly basis to maintain contact with the participants and update 
them on any new information regarding anticipated continuation of study procedures.   
During this time, the study team developed a COVID Impact Survey, which was 
administered by a data collector via telephone or email to all enrolled participants between May 
4, 2020 and July 5, 2020. All participants additionally completed selected Patient Reported 
Outcomes (PROs) that were previously administered at study enrollment (baseline) to evaluate 
changes in depression, anxiety, quality of life (QOL) and MS symptomatology during the time 
period in which lockdown restrictions were in place.  Survey administration occurred after 
lockdown orders and the resultant implications were evident across all data collection centers as 
lockdown was in place; this is an important methodological detail due to the fact that higher 
mean levels of psychiatric symptoms (stress, anxiety, depression) have been observed after the 
sampled population began to experience the effects of stay at home orders [7].  The time between 




Assessments: Assessments in the current study included the COVID Impact Interview and several 
PROs administered at baseline and re-administered during lockdown. 
The COVID Impact Interview was developed by the study team specifically for use in this study 
in an effort to evaluate the impact of the COVID-19 pandemic and lockdown orders on 
individuals with PMS across the participating 11 centers, representing 6 countries in North 
America and Europe. It consists of 22 questions related to self and family exposure to COVID-
19, length of time under lockdown orders, activities during lockdown, disease symptomatology 
and interactions with healthcare providers. A set of questions assessing the impact of the 
pandemic on psychological, financial and physical well-being were included with responses 
recorded on an integer scale (0-10, with 0 being no impact and 10 being maximal impact). The 
survey was administered in the individual’s native language. Results were examined in response 
to each specific question. 
The Hospital Anxiety Depression Scale (HADS) is widely used to assess psychological distress in 
non-psychiatric patients. It consists of two subscales, measured via 14 items, seven items for the 
anxiety subscale (HADS-Anxiety) and seven for the Depression (HADS-Depression) subscale 
[22]. Overall, it has demonstrated satisfactory psychometric properties in several different 
populations, including MS [23-26]. Each item is scored on a response-scale with four 
alternatives ranging between 0 and 3 and a higher score indicates greater anxiety or 
depression. The HADS-depression cutoff for clinical depression was defined as scores ≥ 8.0 
[27].  
The Beck Depression Inventory -II (BDI-II)[28]  is an easily administered, 21-item scale that 
assesses various aspects of depression, useful in determining the presence and severity of 
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depressive symptoms. Each item is concerned with a specific aspect of depression (mood, 
motivation, appetite) and contains four statements of graded severity expressing how a person 
might think or feel about that particular aspect of depression. The total score is the sum of all 
statements endorsed by the participant. A higher score indicates greater depression.  
The Multiple Sclerosis Impact Scale (MSIS-29) is a disease specific measure of the impact of 
MS. It consists of 29-items, 20 associated with a physical scale and 9 associated with a 
psychological scale where the sum of each scale is transformed to a scale of 0-100 and higher 
scores indicating worse health [29]. Items ask about the impact of MS on day-to-day life in the 
past two weeks rated on a 5-point Likert scale. The MSIS-29 has strong reliability and validity in 
MS samples [29], with existing evidence supporting its responsiveness in rehabilitation trials 
[30]. 
The EuroQol (EQ-5D)[31] is a widely used measure of QOL developed in Europe, often used in 
cost-effectiveness analyses. It evaluates QOL across 5 dimensions: mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression.  
 
Analyses: Changes in responses from baseline to lockdown were evaluated using paired t-tests 
and Wilcoxon signed rank tests. Independent sample t-tests were utilized to examine sex 
differences (male versus female) in response patterns. Pearson (or Spearman, when appropriate) 
correlation coefficients examined the relationships between the COVID-19 Impact Interview and 
changes in specific PROs as well the relationship between EDSS, MS disease duration, baseline 




Longitudinal Changes on PROs 
Mean scores across both time points on the outcome measures are presented in Table 3. 
In regard to the impact of COVID-19 on MS symptomatology in daily life, no significant 
differences were noted on the MSIS-29 from baseline to lockdown.  Two measures of depressive 
symptoms were administered. No significant differences were noted on the BDI-II from baseline 
to lockdown; however, a significant difference was noted on the HADS-Depression scale from 
baseline to lockdown (p=0.033), with a small increase in depression symptoms noted at the 
lockdown follow-up (Table 3). Further analyses indicate that this difference was driven by a 
substantial increase in depressive symptoms in the sample from Belgium, while the remaining 5 
countries show similar levels of change (p<0.001; Table 4).  No significant difference was noted 
in regard to the number of patients meeting the HADS-depression cutoff for clinical depression, 
defined as scores ≥ 8.0. No significant difference was noted from baseline to lockdown on the 
HADS-Anxiety Scale or any of the EQ-5D scales. 
 
Sex Differences 
Independent sample t-tests were utilized to examine sex differences (male versus female) 
in response patterns.  No significant differences were noted between males and females in 
symptoms of depression and anxiety, or overall QOL.   
  
COVID Impact Interview 
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 In regard to the impact of COVID-19 on the study population, only 5 of the 131 
respondents reported that he/she had been infected with COVID-19, with 15 reporting infections 
in other family members. 31 individuals knew someone that died from the virus. The majority of 
participants reported some impact of the virus on their psychological well-being (Figure 1), 
while little financial impact was reported. 
 In regard to activities during lockdown, 90% of respondents reported undertaking some 
form of cognitive activity, while 71% reported participating in some form of physical activity 
(Figure 2a and 2b).  Overall, respondents reported a high level of social support (with 70% 
responding 8, 9 or 10 on a 10-point Likert scale). Only 57% of respondents reported any 
interaction with their medical team during lockdown orders, with a comparable proportion 
reporting MS symptom changes during the same time period (58%). 
 With only 5 of the 131 respondents reporting COVID-19 infection, statistical significance 
between these respondents and the non-infected respondents could not reliably be determined.  
However, some identifiable differences in these 5 individuals are worth noting qualitatively. An 
increase from baseline to lockdown was noted in the MSIS mental score in those who were 
infected with COVID-19, with an increase of 15.1 (SD=13.5) noted; this indicates a self-
perceived worsening of challenges in daily life due to mental symptomatology.  A similar 
decrement was noted in the MSIS physical score, with an increase of 7.2 (SD=20.07) noted.  
Depressive symptoms also appeared to be negatively impacted, with a 1-point increase on the 
BDI (SD=7.6) and a 1.8 (SD=5.5) point increase on the HADS-depression. 
 
Relationships between PROs and COVID Responses 
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 No significant relationships were noted between MS disease duration, EDSS, or SDMT 
z-score (processing speed) and changes in depression and anxiety (range of r values: -0.08-0.13).  
Significant correlations were noted between differences in the MSIS-29 Mental Scale 
from baseline to lockdown and the degree to which the respondents felt the pandemic impacted 
their physical well-being (r= -0.24, p=0.009), psychological well-being (r= -0.20, p<0.03) and 
MS disease course  (r= -0.21, p= 0.02).  As perceived impact of MS symptoms on mental 
functioning increased during lockdown, participants similarly reported greater impact on 
physical and psychological well-being and MS disease course.  Significant correlations were also 
noted between differences in the HADS-depression scale and the degree to which the pandemic 
negatively influenced MS disease course (r= -0.19, p=0.048) and the EQ5D Anxiety / 
Depression scale and the degree to which the respondent felt the pandemic impacted his/her 
psychological well-being (r= -0.20, p=0.03).  
 
Discussion 
No statistically significant changes in perceived MS symptomatology were noted from 
baseline to the COVID follow-up conducted during lockdown in our sample of individuals with 
PMS. Despite the fact that the majority of participants reported some impact of the virus on their 
psychological well-being on the COVID Impact Interview, we saw little change in regard to 
symptoms of depression and anxiety and overall QOL on standardized PROs. The international 
composition of our sample indicates that these findings are largely consistent across widely 
dispersed geographical locations.  
There are several potential explanations for this pattern of results. First, one must 
consider the impact of diligence in self-protection on psychological well-being. Others have 
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hypothesized that individuals with a significant medical history may feel increased vulnerability 
to COVID-19 [34].   It is possible that individuals with PMS were diligent about protecting 
themselves from very early in the pandemic because of their increased risk of infection and 
subjective feelings of vulnerability. Their efforts for self-protection may have increased their 
level of comfort because they were diligent in following safety precautions, thus mitigating their 
anxiety and depression. This may have resulted in less anxiety and depression symptoms than 
what might be expected under normal circumstances and seen in the general population. 
Additionally, individuals with PMS already experience substantial physical disability that 
often leads to some degree of isolation in daily life. Thus, the drastic societal changes in social 
interaction due to lockdown orders may have been less impactful for this population due to the 
fact that their activities have already been significantly restricted for quite some time.  Social 
isolation has been shown to have significant impact on mental health in numerous studies [32], 
with social isolation and loneliness being associated with depression in the general population 
[33].  It may be that our sample of individuals with PMS were already accustomed to some 
degree of social isolation, thus easing the transition to lockdown. 
The impact of experience in living with medical uncertainly also cannot be 
overestimated. Studies conducted early in the COVID-19 outbreak in China concluded that fear 
of the unknown and uncertainty can lead to increased stress, anxiety and depression [35]. 
Zandifar and colleagues similarly highlighted the role of unpredictability, uncertainty, and 
seriousness of the disease in such psychiatric symptomatology [36]. However, individuals with 
MS live with medical uncertainty from the time of diagnosis and thus have experience dealing 
with the associated discomfort.  Individuals with PMS thus may not be experiencing the 
psychological discomfort that comes with such uncertainty in the face of COVID-19.  The 
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psychiatric symptomatology they are experiencing is thus less than that which is seen in the 
general population.  
 Finally, the large majority of our sample additionally reported engagement in both 
cognitive and physical activities during lockdown.  This is an encouraging finding and likely 
contributed to the little change observed in psychiatric symptomatology over the same time 
period. One of the aims of the parent RCT of the present study is to encourage a more active 
lifestyle and participants were all within some phase of the RCT when lockdown was initiated. 
Had the RCT run its full course prior to lockdown, engagement in cognitive and physical 
activities may have influenced changes in psychiatric symptomatology in a significantly positive 
way.     
 These same factors may be at play in the lack of significant differences seen in 
depression or anxiety between males and females in our PMS sample. This is contrary to that 
which is observed in the general population, in which females present with higher rates of 
anxiety and depression as compared with males [14-18]. Our sample is indeed 63% female, 
consistent with MS being more common in females. This larger proportion of females in which 
uncertainty may already be a normal component of life could potentially lead to less depression 
and anxiety in our female sample as compared to that which has been seen in the general 
population. 
It is interesting to note that only 5 of the 131 respondents reported that he/she had been 
infected with COVID-19; this represents a 4% infection rate. This is however a higher infection 
rate than that which is seen in the general population within each country represented.  The 
impact of the infection on MS symptoms was also quite evident, with those infected with 
COVID-19 showing worsening on both the MSIS-29 mental score (15-point increase) and the 
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MSIS-29 physical score (7-point increase). This is compared to a change of less than 1 on each 
of these scores in the full sample, indicating that infection with COVID-19 had a tremendous 
impact on the MS-related symptomatology and daily limitations that individuals with PMS 
experience. The change in depression scores in this subgroup however were consistent with 
changes noted in the full sample.   
No relationship was noted between baseline MS-disease related variables (disease 
duration, processing speed ability, EDSS) and changes in depression, anxiety and QOL from 
baseline to lockdown. However, relationships were noted between changes in responses on the 
PROs and COVID Impact Interview.  The perceived impact of the pandemic on physical and 
psychological well-being was correlated with the impact of MS symptomatology on daily life, as 
measured by the MSIS-29 mental scale, as well as changes in psychiatric symptomatology 
(HADS–depression, EQ5D Anxiety/Depression).  These relationships attest to the importance of 
one’s perception of the impact of the pandemic on standardized measures of disease 
symptomatology, emotional functioning and QOL.  
  There are some limitations to the current study that deserve mention. Given that the full 
RCT through which this data was collected did not include a measure of stress, we did not 
measure changes in stress from baseline to lockdown.  Given that elevated stress has been 
documented in the general population during the COVID-19 pandemic, these data would have 
been advantageous.  Additionally, no questions were included regarding the severity of infection 
if an individual was indeed infected. We therefore could not examine the relationship between 
the severity of COVID-19 and changes in psychiatric symptomatology or the impact of MS on 
daily life. Another factor not examined in the current study was exposure to the news and 
potential misinformation. In the general population, depressive symptoms can be exacerbated by 
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misinformation and fabricated reports about COVID-19 [15] and people who follow COVID-19 
the most in the news experience more anxiety [37], but we were unable to examine this 
relationship in PMS.  In addition, the lockdown follow-up was completed toward the end of the 
lockdown period across all sites.  It is possible that the time in lockdown had afforded patients 
the time to adjust emotionally to the lockdown and thus exhibit less emotional symptomology. 
Sample bias could have also potentially impacted our pattern of results. The current sample 
engaged / or was engaging in a 3-month intensive training study; these individuals could 
potentially have higher levels of self-efficacy and/or resilience. The many strengths of the study 
however, far outweigh these limitations.  Specifically, the ongoing parent RCT allowed the 
comparison of pre-pandemic depression, anxiety and QOL to the same ratings completed during 
lockdown in a fairly large sample of individuals with PMS in 6 different countries.  These unique 
data thus provide comparative values that are rarely available. 
Overall, findings indicate that individuals living with PMS through the COVID-19 
pandemic are adapting well to date.  That is, minimal change was noted from pre-COVID status 
to assessments conducted during COVID-19 lockdown on depression, anxiety and QOL.  
Minimal changes were additionally noted in the impact of MS-related symptoms on daily life 
functioning on the limited measures utilized to assess this construct, with the exception of those 
infected with COVID-19.  While the infection rate observed in our sample was higher than that 
which is seen in the general population, even those who contracted COVID-19 showed minimal 
change from pre-COVID depression, anxiety and QOL to ratings of depression, anxiety and 
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Table 1: Sample Demographics 
Demographic and Clinical Characteristics (n=131) 
Age (in years), mean (SD) 52.1 (6.9) 
Education (in years) , mean (SD) 13.1 (3.1) 
Female (%) 63.4% 
Country (%)  
    Belgium 6.9% 
    Canada 12.2% 
    Dennmark 9.2% 
    United Kingdom 20.6% 
    Italy 44.2% 
    United States 6.9% 
Disease Duration, mean (SD) 14.4 (9.1) 
Baseline SDMT score (z) , mean (SD) -2.2 (0.79) 
EDSS score, median (25th percentile, 75th percentile) 6.0 (4, 6.5) 
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Table 2: Inclusion and exclusion criteria 
Inclusion Criteria 
Criteria Requirement Screening 
Diagnosis Clinically Definite PMS Telephone 
Age 25-65 years Telephone 
Ambulation NOT wheelchair dependent (EDSS<7) Telephone 
Processing Speed 
Impairment 
SDMT Total Score ≥1.282 SD below 
published normative data (10th percentile). 
In-person 
Exclusion Criteria 
Substance Abuse Use of illicit drugs, PCP, LSD, Stimulants,  
Amphetamines, Barbiturates, etc. 
(Cannabis use was acceptable). 
Telephone 
Neurological History A history of central nervous system disease 
other than PMS (e.g. stroke, Parkinson´s 
disease, traumatic brain injury) 
Telephone 
Severe Mental Illness Psychotic symptoms, Bipolar Disorder, 
schizophrenia 
Telephone 
Medication use Steroids use within the past 3 months Telephone 
Transport Unable or unwilling to travel to the center for 
testing and training or requiring 
transportation by ambulance 
Telephone 
Medical Contraindication No medical clearance from family doctor  Telephone 
Current Exercise Routine Currently performing medium to high 
intensity workouts according to the Exercise 
History Screening Questionnaire (GLTEQ 
score <23). 
Telephone 
Visual Acuity Corrected near vision of at least 20/70 (to 
see the test materials).  Severe nystagmus 
according to neurologist ratings. 
In-person 
Depression Beck Depression Inventory II Score ≥ 29 In-person 
Language Comprehension Token Test Score   ≥ 29 In-person 
MRI compatibility (MRI sites 
only) 







Table 3: Mean Responses on the BDI, HADS  and MSIS*  
 
Variable Baseline Lockdown p-value 
BDI Total Score 11.3 (7.5) 12.1 (9.2) 0.329 
HADS Depression Score 5.8 (3.7) 6.7 (4.6) 0.033 
HADS Anxiety Score 5.9 (4.3) 6.0 (4.3) 0.748 
MSIS-29 Physical Score 45.3 (21.6) 47.2 (22.4) 0.595 
MSIS-29 Mental Score 34.3 (22.7) 35.1 (22.6) 0.915 
EQ5D Mobility   0.707 
          No Problems 16(12.5) 11(8.8)  
          Slight  25(19.5) 27(21.6)  
          Moderate  51(39.8) 59(47.2)  
          Severe 36(28.1) 27(21.6)  
          Unable 0(0.0) 1(0.80)  
EQ5D Self Care   0.127 
          No Problems 67(52.3) 57(45.6)  
          Slight  35(27.3) 37(29.6)  
          Moderate  21(16.4) 25(20.0)  
          Severe 5(3.9) 6(4.8)  
EQ5D Usual Activities   0.709 
          No Problems 22(17.3) 21(16.8)  
          Slight  43(33.9) 31(24.8)  
          Moderate  42(33.1) 60(48.0)  
          Severe 20(15.7) 11(8.8)  
          Unable 0(0.0) 2(1.6)  
EQ5D Pain   0.082 
          No Problems 35(27.3) 28(22.4)  
          Slight  36(28.1) 36(28.8)  
          Moderate  45(35.2) 42(33.6)  
          Severe 9(7.0) 17(13.6)  
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          Unable 3(2.3) 2(1.6)  
EQ5D Anxiety/Depression   0.087 
          No Problems 67(52.3) 60(48.0)  
          Slight  38(29.7) 35(28.0)  
          Moderate  20(15.6) 23(18.4)  
          Severe 3(2.3) 5(4.0)  
          Unable 0(0.0) 2(1.6)  































BDI -0.72(8.1) 1.1(6.2) -4.3(10.8) 1.6(4.0) -1.7(7.4) -0.14(8.6) 0.11(4.9) 0.40 
HADS-
depression 
-0.79(4.0) -6.7(6.1) -0.13(3.2) 0.25(2.8) -0.43(2.6) -0.53(4.1) 0.25(1.6) <0.001 
HADS-
anxiety 
-0.16(4.2) -1.4(5.2) -0.93(5.6) 0.33(3.4) 0.08(2.7) 0.09(4.6) -0.50(2.8) 0.88 
MSIS- 
physical 
-0.74(16.5) 0.56(11.9) -10.1(22.1) 2.4(12.7) -1.7(11.1) 0.55(16.3) 11.8(20.6) 0.05 
MSIS - 
Mental 
0.02(19.7) 0.61(5.5) -7.2(28.8) 2.0(16.4) 2.8(19.2) 0.17(20.1) 1.6(10.5) 0.74 
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>30 minutes / day 
n=26 
